��������

Helgi Van De Velde is an established leader in oncology with significant experience in clinical research and program development. Currently serving at Sanofi since February 2018, Helgi holds the positions of Head of Hematologic Malignancies Strategies and Late Development, as well as Vice President Global Program Head for Multiple Myeloma. Previous roles include Vice President of Oncology Clinical Research at Takeda Oncology, where Helgi contributed to the global regulatory approval of NINLARO (ixazomib) for relapsed multiple myeloma, and Senior Director of Oncology Clinical Research at Johnson & Johnson, leading the global development of VELCADE (bortezomib) and Siltuximab (SYLVANT). Educational credentials include an MD PhD in Medicine and Molecular Oncology from Cath University Leuven and extensive fellowships in oncology at the National Cancer Institute and the FDA's CDER Oncology Division.